Research

Isomorphic Labs: Funding, Partners and Clinical Trial Status in 2026

Isomorphic Labs raised $2.1 billion in May 2026 and has deals with Lilly, Novartis and Johnson & Johnson. Its first clinical trial target moved from end of 2025 to end of 2026. Status as of November 13, 2026.

By Ramanath, CTO & Co-Founder at Presenc AI · Last updated: November 2026

Isomorphic Labs, the drug discovery company spun out of Google DeepMind in 2021, raised $2.1 billion in a Series B on May 12, 2026, led by Thrive Capital. It has research deals with Eli Lilly, Novartis and Johnson & Johnson. As of November 13, 2026, we found no Isomorphic study on ClinicalTrials.gov, and press coverage from November 3 said no candidate had entered human trials. The company's stated target is a first clinical trial by the end of 2026, a year later than first said.

Funding Rounds

DateRoundAmountLeadOther investors
2021Founded as an Alphabet companyNot disclosedAlphabet
March 2025First external round$600MThrive CapitalNot listed in our sources
May 12, 2026Series B$2.1BThrive CapitalAlphabet and GV (existing). MGX, Temasek, CapitalG and the UK Sovereign AI Fund (new)

The valuation was not disclosed. Reuters said the company did not respond on valuation. The two external rounds add up to $2.7 billion, which is the figure Sacra gives. R&D World put total outside capital at about $2.6 billion. Neither figure includes Alphabet's earlier funding.

The company said the Series B will pay for further work on its drug design engine, known as IsoDDE, for moving its own programmes toward the clinic, and for hiring in AI, engineering, drug design and clinical roles.

Partners and Deal Values

PartnerAnnouncedUpfrontMilestonesScope
Eli LillyJanuary 2024$45MUp to $1.7BSmall molecules against multiple targets
NovartisJanuary 2024$37.5M, plus funding for some research costsUp to $1.2BSmall molecules against three targets
Novartis, expansionFebruary 18, 2025Same terms as the original dealSame terms as the original dealUp to three more research programmes
Johnson & JohnsonJanuary 20, 2026Not disclosedNot disclosedMulti-target research across small molecules, antibodies, peptides and molecular glues

The two 2024 deals together came to $82.5 million upfront and up to $2.9 billion in milestones. The milestone figures are contingent. See biobucks for why the upfront number is the one to compare. No approved medicine has come from any of the three partnerships.

The Clinical Trial Timeline as Stated

WhenWhoWhat was said
2025Demis Hassabis, founder and CEOAI-designed drugs would be in clinical trials by the end of 2025, as later summarised by Reuters
January 20, 2026Demis Hassabis, at a World Economic Forum event in DavosThe company expects its first clinical trials by the end of 2026, per Reuters
May 12, 2026Company press release on the Series BSays funds will move programmes "toward the clinic". Gives no trial date
September 2026Sacra company profileNo clinical candidate had been named publicly
November 2, 2026Max Jaderberg, president, at a Bloomberg event in LondonDescribed the company as in its "first innings", according to The Neuron
November 3, 2026The NeuronNo Isomorphic candidate had entered human trials and the company had not confirmed any trial start

A search of ClinicalTrials.gov on November 13, 2026 for studies sponsored by Isomorphic returned no records. A trial run by a partner or under another sponsor name would not appear in that search.

Some websites have reported an Isomorphic drug called ISL-001 in Phase 2. We found no registry record, company statement or established outlet supporting that, and it contradicts the reporting above. A compound called ISM8969 that appears in some articles about Isomorphic belongs to a different company, Insilico Medicine.

Pipeline

The company says it has both partnered programmes and wholly owned ones, and has not named a candidate. R&D World reported 17 active programmes across oncology, immunology and cardiovascular disease in May 2026. We could not confirm that count in a company source. Offices are in London, Cambridge, Massachusetts, and Lausanne.

For comparison with compounds from other AI drug companies that are already in trials, see AI-designed drugs in clinical trials. For how Isomorphic differs from the life-science products of OpenAI and Anthropic, see Claude Science vs GPT-Rosalind vs Isomorphic Labs.

Methodology

Round details come from Isomorphic's May 12, 2026 press release. The 2025 round, the Davos statement and the earlier target come from Reuters, read via Investing.com. Totals come from Sacra and R&D World. The Johnson & Johnson deal is from Isomorphic's announcement, and the 2024 terms from BioSpace. November status is from The Neuron and our own query of the ClinicalTrials.gov API. Status as of November 13, 2026.

Frequently Asked Questions

Isomorphic Labs raised $2.1 billion in a Series B announced May 12, 2026, after a $600 million first external round in March 2025. Both were led by Thrive Capital. That is $2.7 billion in disclosed external funding. R&D World put the total at about $2.6 billion. Alphabet funded the company before that and the amount is not public.
Not as far as public records show on November 13, 2026. ClinicalTrials.gov had no study sponsored by Isomorphic, and coverage on November 3 said no candidate had entered human trials. The company target, stated in January 2026, is a first clinical trial by the end of 2026.
The valuation was not disclosed in the May 2026 Series B. Reuters reported that the company did not respond to a question about it.
Eli Lilly and Novartis, both announced in January 2024, and Johnson & Johnson, announced January 20, 2026. Lilly paid $45 million upfront with up to $1.7 billion in milestones. Novartis paid $37.5 million upfront with up to $1.2 billion in milestones and expanded the deal in February 2025. Johnson & Johnson terms were not disclosed.
The company has not given a public reason. Reuters reported on January 20, 2026 that the target had moved from the end of 2025 to the end of 2026.

Hire agents, not agencies.

Presenc is a team of AI agents that builds the pages your buyers search for, and a person checks every one. We take on a few teams at a time.

Request access